Remdesivir for Patients with COVID-19 (Adults and Adolescents 12 years and older) Guidelines for NHS GGC (1021)

Warning

exp date isn't null, but text field is

Abstract

Remdesivir is an adenosine nucleotide prodrug that is metabolised intracellularly to form the pharmacologically active substrate remdesivir triphosphate. Remdesivir triphosphate inhibits SARS-CoV-2 RNA polymerase which perturbs viral replication.

Current evidence shows that remdesivir improves clinical outcomes in both hospitalised and non-hospitalised patients with COVID-19.

Resources

Use the button below to access this resource item.

Access this resource

Last reviewed: 23 March 2022

Next review: 08 April 2023

Author(s): Samantha Carmichael

Version: 1

Approved By: NHSGGC Covid-19 Tactical Group (Acute)

Document Id: 1021